Spectrum of gastric malignancy on 18F-FDG PET/CT: a pictorial essay


      A wide variety of malignant gastric diseases can be detected, staged, and followed on 18F-FDG PET/CT. Although the PET/CT findings are often nonspecific and some can be seen in certain benign gastric diseases, the aim of this atlas was to demonstrate that the wide histological spectrum of gastric tumors that can be evaluated, staged, and followed with PET/CT is much broader than current medical literature would suggest. PET/CT readers and oncologists should be aware of the utility of PET/CT in these tumors and the imaging characteristics and patterns of 18F-FDG uptake that can be demonstrated in these cases.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Imaging
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Koga H
        • Sasaki M
        • Kuwabara Y
        • et al.
        An analysis of the physiological FDG uptake pattern in the stomach.
        Ann Nucl Med. 2003; 17: 733-738
        • Tian J
        • Chen L
        • Wei B
        • et al.
        The value of vesicant 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) in gastric malignancies.
        Nucl Med Commun. 2004; 25: 825-831
        • Yun M
        • Choi HS
        • Yoo E
        • Bong JK
        • Ryu YH
        • Lee JD
        The role of gastric distention in differentiating recurrent tumor from physiologic uptake in the remnant stomach on 18F-FDG PET.
        J Nucl Med. 2005; 46: 953-957
        • Imperiale A
        • Cimarelli S
        • Sellem DB
        • Blondet C
        • Contantinesco A
        Focal F-18 FDG uptake mimicking malignant gastric localizations disappearing after water ingestion on PET/CT images.
        Clin Nucl Med. 2006; 31: 835-837
        • Kamimura K
        • Fujita S
        • Nishii R
        • et al.
        An analysis of the physiological FDG uptake in the stomach with the water gastric distention method.
        Eur J Nucl Med Mol Imaging. 2007; 34: 1815-1818
        • Cohade C
        • Osman M
        • Nakamoto Y
        • et al.
        Initial experience with oral contrast in PET/CT: phantom and clinical studies.
        J Nucl Med. 2003; 44: 412-416
        • Zhu Z
        • Li F
        • Zhuang H
        Gastric distension by ingesting food is useful in the evaluation of primary gastric cancer by FDG PET.
        Clin Nucl Med. 2007; 32: 106-109
        • Polk DB
        • Peek RM
        Helicobacter pylori: gastric cancer and beyond.
        Nature Reviews Cancer. 2010; 10: 403-414
        • Jones RG
        • Trowbridge DB
        • Go MF
        Helicobacter pylori infection in peptic ulcer disease and gastric malignancy.
        Front Biosci. 2001; 6: 213-226
        • Huang JQ
        • Sridhar S
        • Chen Y
        • Hunt RH
        Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer.
        Gastroenterology. 1998; 114: 1169-1179
        • McDivitt JD
        • Arluk GM
        • Turton DB
        Incidental detection of Helicobacter pylori gastritis during FDG PET scanning for lymphoma.
        Clin Nucl Med. 2008; 33: 113-114
        • Ak I
        • Gulbas Z
        Intense F-18 FDG accumulation in stomach in a patient with Hodgkin lymphoma: Helicobacter pylori infection as a pitfall in oncologic diagnosis with F-18 FDG PET imaging.
        Clin Nucl Med. 2005; 30: 41
        • Wong BC
        • Lam SK
        • Wong WM
        • et al.
        Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial.
        JAMA. 2004; 291: 187-194
      1. Cancer fact sheet No. 297. World Health Organization, 2011
        • Yoshioka T
        • Yamaguchi K
        • Kubota K
        • et al.
        Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer.
        J Nucl Med. 2003; 44: 690-699
        • Kim SK
        • Kang KW
        • Lee JS
        • et al.
        Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer.
        Eur J Nucl Med Mol Imaging. 2006; 33: 148-155
        • Stahl A
        • Ott K
        • Weber WA
        • et al.
        FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings.
        Eur J Nucl Med. 2003; 30: 288-295
        • Mukai K
        • Ishida Y
        • Okajima K
        • Isozaki H
        • Morimoto T
        • Nishiyama S
        Usefulness of preoperative FDG-PET for detection of gastric cancer.
        Gastric Cancer. 2006; 9: 192-196
        • Erasmus JJ
        • Rohren EM
        • Hustinx R
        PET and PET/CT in the diagnosis and staging of esophageal and gastric cancers.
        PET Clin. 2008; 3: 135-145
        • Hoffmann M
        • Kletter K
        • Diemling M
        • et al.
        Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-d-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type.
        Ann Oncol. 1999; 10: 1185-1189
        • Ambrosini V
        • Rubello D
        • Castellucci P
        • et al.
        Diagnostic role of 18F-FDG-PET in gastric MALT lymphoma.
        Nuc Med Review. 2006; 9: 37-40
        • Radan L
        • Fischer D
        • Bar-Shalom R
        • et al.
        FDG avidity and PET/CT patterns in primary gastric lymphoma.
        Eur J Nucl Med Mol Imaging. 2008; 35: 1424-1430
        • Beal KP
        • Yeung HW
        • Yahalom J
        FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases.
        Ann Oncol. 2005; 16: 473-480
        • Kumar R
        • Xiu Y
        • Potenta S
        • et al.
        18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
        J Nucl Med. 2004; 45: 1796-1803
        • Gayed I
        • Vu T
        • Iyer R
        • et al.
        The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
        J Nucl Med. 2004; 45: 17-21
        • Kamiyama Y
        • Aihara R
        • Nakabayashi T
        • et al.
        18F-Fluorodeoxyglucose positron emission tomography: useful technique for predicting malignant potential of gastrointestinal stromal tumors.
        World J Surg. 2005; 29: 1429-1435
        • Choi H
        • Charnsangavej C
        • de Castro Faria S
        • et al.
        CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings.
        AJR Am J Roentgenol. 2004; 183: 1619-1628
        • Van den Abbeele AD
        The lessons of GIST—PET and PET/CT: a new paradigm for imaging.
        The Oncologist. 2008; 13: 8-13
        • Van den Abbeele AD
        • for the GIST Collaborative PET Study Group Dana- Farber Cancer Institute, Boston, Massachusetts; OHSU, Portland, Oregon, Helsinki University Central Hospital, Turku University Central Hospital, Finland, Novartis Oncology
        F18-FDG-PET provides early evidence of biological response to STI571 in patients with malignant gastrointestinal stromal tumors (GIST).
        Proc Am Soc Clin Oncol. 2001; 20: 362a
        • Solcia E
        • Klöppel G
        • Sobin LH
        Histological typing of endocrine tumours.
        in: World Health Organization: International Histological Classification of Endocrine Tumours. Springer, New York2000
        • Matsui K
        • Jin XM
        • Kitagawa M
        • et al.
        Clinicopathologic features of neuroendocrine carcinomas of the stomach: appraisal of small cell and large cell variants.
        Arch Pathol Lab Med. 1998; 122: 1010-1017
        • Salaun PY
        • Grewal RK
        • Dodamane I
        • et al.
        An analysis of the 18F-FDG uptake pattern in the stomach.
        J Nucl Med. 2005; 46: 48-51
        • Tytgat GN
        • Bartelink H
        • Bernards R
        • et al.
        Cancer of the esophagus and gastric cardia: recent advances.
        Diseases of the Esophagus. 2004; 17: 10-26
        • Flamen P
        PET Scan to predict response in esophageal cancer.
        in: Proceedings Cancer of Esophagus and Gastric Cardia: from Gene to Cure. European Cancer Centre, Amsterdam2002 ([abstract S13])
        • Grégoire V
        • Lonneux M
        The role of functional imaging for assessing treatment response in esophageal tumors.
        in: Proceedings Cancer of Esophagus and Gastric Cardia: from Gene to Cure. European Cancer Centre, Amsterdam2002 ([abstract S36])
        • Weber WA
        • Ott K
        • Becker K
        • et al.
        Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging.
        J Clin Oncol. 2001; 19: 3058-3065
        • Menuck LS
        • Amberg JR
        Metastatic disease involving the stomach.
        Dig Dis. 1975; 20: 903-913
        • Chamroonrat W
        • Zhuang H
        • Houseni M
        • et al.
        Malignant lesions can mimic gastric uptake on FDG PET.
        Clin Nucl Med. 2006; 31: 37-38
        • Israel O
        • Yefremov N
        • Bar-Shalom R
        • et al.
        PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake: incidence, localization patterns, and clinical significance.
        J Nucl Med. 2005; 46: 758-762
        • Kamel EM
        • Thumshirn M
        • Truninger K
        • et al.
        Significance of incidental 18F-FDG accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results.
        J Nucl Med. 2004; 45: 1804-1810